Vivera’s influential Board of Directors, Advisory Board and Management Team is comprised of experts with professional backgrounds ranging from technology, science, healthcare, compliance, business, finance, professional sports and media.
Best in Class
Vivera will be one of the first companies to pursue a U.S. Food and Drug Administration (FDA) New Drug Application (NDA) with its global, exclusive license to the novel, TABMELT® sublingual drug delivery technology.
While Vivera pursues continued research and development and long-term new drug approvals, Vivera is unique when compared to other pharmaceutical companies where it is and expects to be profitable on a recurring basis.
Through its multiple divisions, unique products, proprietary distribution networks and strategic partners, the company intends to rapidly expand through the expertise of its division managers and its continued path to innovate.
Vivera Pharmaceuticals, Inc. is an innovative, science-driven pharmaceutical company focused on opioid deterrence and cessation and non-addictive solutions for pain management.
In addition to its pharmaceutical and medical device products, the Company has global exclusivity to license the patented and provisionally patented, TABMELT® sublingual drug-delivery system for pharmaceutical use.
With multiple divisions, Vivera® is vertically integrated with patented technology, manufacturing capabilities, and distribution for its products.